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Aim: To analyze whether comprehensive assessment of haemostatic system components, in particular, indices of coagulation and fi-
brinolytic systems along with functionally related proteins, could be indicative of upper respiratory tract (URT) cancer progression. 
Materials and Methods: Indices of coagulation and fibrinolytic systems along with functionally related proteins, in particular, trypsin-
like amidolytic activity, trypsin-like proteolytic activity, thrombin-like amidolytic activity, elastase-like amidolytic activity, fibrino-
lytic activity, potential amidolytic plasmin activity, content of fibrinogen, antithrombin III, α1-proteinase inhibitor, and α2-macroglobulin, 
and prothrombin time were evaluated in blood plasma of patients with URT cancer of II (n = 10) and III (n = 25) stages with the use 
of routine biochemical methods. Results: For both groups of patients with URT cancer there have been shown notable differences for 
the majority of the studied indices, especially the indexes of proteolytic activities, from these of healthy donors, and in the case of URT 
cancer of III stage they reached statistical significance. In contrary, the changes in the content of antithrombin III, α1-proteinase 
inhibitor, and α2-macroglobulin were insignificant. In both groups of patients significant increase of fibrinogen content has been 
registered, while the content of soluble fibrinogen didn’t change. Also, in both groups of patients there a significant increase of poten-
tial activity of plasminogen was documented, while clot lysis time was significantly increased only in patients with III stage URT 
cancer. Multifactorial analysis of haemostatic system indices evidenced for efficacy of their combined use for evaluation of URT 
cancer progression risk. Conclusion: Combined use of fibrinogen and α2-macroglobulin content and the level of amidolytic thrombin-
like activity could serve as an indicator of URT cancer progression.
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The raising cancer incidence is among the most 
serious medical and social problems of our time. 
According to the Cancer Register of Ukraine, the 
annual mortality from malignant processes is close 
to 100 thousands cases, and the annual morbidity 
reaches 160 thousands cases (0.2 and 0.32% of the 
country population, respectively). 7.5–8% of cancer 
cases are related to the cancer of upper respiratory 
tract (URT), which incidence has increased by 1.6 times 
during last 10 years [1]. As it is commonly accepted, 
the early detection of a disease is a key to its effective 
therapy. However, cancer is usually detected by its late 
clinical manifestations, and no universal index for early 
cancer detection has been found so far [2]. However, 
according to the data of some researchers, not a single 
index but a combination of several cancer-related 
biochemical alterations in components of haemostatic 
system (HS), could be considered promising [3].
It is well known that HS consists of two oppositely 
directed enzymatic sub-systems, which provide the 
formation of fibrin clot and its lysis. The majority of en-
zymatic HS components are trypsin-like proteinases 
that are synthesized as inactive pro-enzymes with 
their following processing into active forms via high-
selective enzymatic cleavage. In turn, these activated 
proteinases are activators for other pro-enzymes, pro-
factors and are under strict control of high-selective 
protein inhibitors [4, 5]. Disturbances of this highly 
regulated systems lead to the disturbance of various 
physiological processes that are aligned with nume-
rous diseases. Malfunction of proteolysis significantly 
disturbs both fibrin clotting and fibrinolysis, comple-
ment and kinine systems [6, 7], and causes tissue 
damage and uncontrolled tumor growth [8–12]. Can-
cer cells are known to produce proteolytic enzymes, 
which affect haemostasis as well as promote tumor in-
vasion and metastasis [13, 14]. Non-functional proteo-
lysis plays a prominent role in post-operative compli-
cations, such as thrombosis and bleeding, recurrence 
and metastasis [15–17]. It should be underlined that 
a number of HS components is directly involved into 
cancer development [18–20]. Therefore, in the pre sent 
work we aimed to analyze whether comprehensive 
assessment of HS components, in particular, indices 
of coagulation and fibrinolytic systems along with 
functionally related proteins, could be an informative 
tool for prediction of disease progression in patients 
with URT cancer.
MATERIALS AND METHODS
Patients. In the study, 10 patients with primary 
laryngeal cancer of II stage and 25 patients with URT 
cancer of III stage were enrolled. The patients were 
cured in SI “O.S. Kolomiychenko Institute of Otola-
ryngology of National Academy of Medical Sciences 
of Ukraine” in 2008–2010. The patients underwent 
surgical treatment, those with URT cancer of III stage 
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after surgery were treated by radiotherapy. Periphe-
ral blood was taken 1 day before the operation. The 
control group consisted of 24 healthy donors. The 
study has been performed in accordance with ethics 
rules for biomedical research; all patients have given 
an informed consent for the participation in the study.
Biochemical measurements. The samples 
of platelet-delpeted citrate plasma were obtained 
by centrifugation of blood at 1200 g for 20 min.
Trypsin-like amidolytic activity was determined 
by extinction of para-nitroaniline (p-NA) formed 
by splitting of chromogenic substrate — Nα-benzoyl-
D,L-arginine para-nitroanilide (BAPNA) using spec-
trophotometry at 383 nm and was expressed in nmol 
of p-NA per 1 ml of plasma per 1 min [4].
Trypsin-like proteolytic activity (PRA) was deter-
mined by enzymatic cleavage of protamine with follow-
ing evaluation of arginine-containing peptides soluble 
in 20% trichloroacetic acid and was expressed in nmol 
of soluble arginine per 1 ml plasma per 1 min [4].
Thrombin-like amidolytic activity was determined 
by extinction of p-NA formed by splitting of chro-
mogenic substrate — Tos-Gly-L-Pro-L-Arg-para-
nitroanilide (Chromozym TH) using spectrophotometry 
at 405 nm and was expressed in nmol of p-NA per 
1 ml of plasma per 1 min [21].
Elastase-like amidolytic activity was determined 
by extinction of p-NA formed by splitting of chromo-
genic substrate — Suc-L-Ala3-para-nitroanilide using 
spectrophotometry at 410 nm and was expressed 
in nmol of p-NA per 1 ml of plasma per 1 min [22].
Fibrinolytic activity (FA) was evaluated by euglobu-
lin method and expressed as time (min) of fibrin clot 
formation and dissolution [23].
Potential amidolytic plasmin activity was de-
termined by extinction of p-NA formed by splitting 
of chromogenic substrate — H-D-Val-L-Leu-L-Lys-
para-nitroanilide (S-2251) using spectrophotometry 
at 405 nm and was expressed in nmol of p-NA per 
1 ml of plasma per 1 min [24].
The content of fibrinogen was determined by the 
method of Belitser et al. [25].
Prothrombin time (PT) was evaluated by duration (s) 
of plasma coagulation in the presence of thromboplas-
tin and calcium chloride [26].
The content of antithrombin III (AT-III) was deter-
mined by Abildgaarg method [21] and was expressed 
as % of the norm.
The contents of α1-proteinase inhibitor (α1IP) and 
α2-macroglobulin (α2M) were determined by inhibi-
tion of BAPNA lysis with or without soybean trypsin 
inhibitor [4].
Statistical analysis of the data was performed 
using Statistica program. The data were presented 
as M ± m. The differences between the groups were 
analyzed using Student’s t-criterion. The difference 
was considered significant if p < 0.05.
RESULTS AND DISCUSSION
The main indices of plasma coagulation system 
of the patients and healthy donors are presented 
in Table 1. The most significant changes were re-
corded in the patients with URT cancer of III stage: 
the contents of fibrinogen, AT-III, and level of ami-
dolytic thrombin-like activity increased by 1.8-, 1.2- 
and 1.6-fold, respectively. Also, in this group PT was 
significantly higher than in healthy donors. In the 
patients with laryngeal cancer of II stage increased 
PT and fibrinogen content are noted, whereas the level 
of amidolytic thrombin-like activity was close to that 
in control group. In both groups of the patients the 
content of soluble forms of fibrin wasn’t different from 
the normal level. We have conclude that pre-treatment 
levels of fibrinogen, AT-III, and amidolytic thrombin-
like activity in the group of patients with III stage of ma-
lignancy were significantly higher than in patients with 
II stage as well as in control group. These differences 
may be evaluated as the evidence for the dependence 
of these haemostatic indices of the stage of disease.
Таble 1. Indices of clotting system of blood plasma of patients with URT 
cancer
Groups of pa-
tients
Content 
of fibrino-
gen, g/l
Disso-
luble fi-
brin, 
mg%
Prothrom-
bine 
time, s
Content 
of АТ-ІІІ, %
Amidolytic 
thrombine-
like activity, 
nmol p-NA/
(min∙ml)
Patients with 
URT cancer 
of ІІІ stage  
(n = 25)
4.0 ± 0.3
p < 0.001 4.0 ± 0.3
29.0 ± 1.0
p < 0.001
119.0 ± 6.6
p < 0.02
16.0 ± 3.0
p < 0.05
Patients with 
URT cancer 
of ІІ stage  
(n = 10)
3.1 ± 0.2
p < 0.001 4.0 ± 0.8
28.0 ± 1.4
p < 0.02 107.0 ± 5.0 10.2 ± 2.0
Healthy persons 
(control group) 
(n = 24)
2.2 ± 0.1 4.3 ± 0.4 23.5 ± 0.8 100.0 ± 2.7 9.6 ± 1.0
Note: statistically significant differences with control group are marked 
by corresponding p value.
It is known that cancer cell secretion of proteolytic 
enzymes causes the destruction of intercellular matrix 
thus creating favorable conditions for tumor inva-
sion. The activity of proteases are dependent both 
on the level of their production and of their blocking 
by specific inhibitors [27, 28]. The levels of activity 
of proteolytic enzymes and the content of protease 
inhibitors (α2M and α1IP) in blood plasma of the pa-
tients are presented in Table 2. According to these 
data, in the group of patients with UPT cancer of III 
stage the levels of PRA and elastase-like amidolytic 
activity are significantly higher than the correspon-
ding levels in healthy donors, while the content of α2M 
is significantly reduced. PRA in patients with UTR 
cancer of II stage was also significantly increased, but 
lower than in the patients with stage III of the disease. 
The elastase-like amidolytic activity in patients with 
UTR cancer of II stage just tended to be increased 
in comparison to the control group, while the content 
of α2M was reduced in contrary to that in patients with 
III stage. The level α1IP in patients with II stage of URT 
cancer wasn’t different from its reference value.
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Table 2. Characteristics of PRA, elastase-like amidolytic activity and con-
tents of their inhibitors in blood plasma of patients with URT cancer
Groups of patients
PRA, 
nmol Arg/
(min∙ml)
Amidolytic 
elastase-
like activ-
ity, nmol 
p-NA/ 
(h∙ml)
Content 
of α2М, g/l
Content 
of α1IP, g/l
Patients with URT can-
cer of ІІІ stage (n = 25)
78.0 ± 4.0
p < 0,001
14.0 ± 1.7
p < 0.02
1.5 ± 0.1
p < 0.001
2.5 ± 0.2
p < 0.05
Patients with URT can-
cer of ІІ stage (n = 10)
72.5 ± 5.1
p < 0.01 10.3 ± 1.5 1.6 ± 0.2 1.8 ± 0.2
Healthy persons (con-
trol group) (n = 24) 55.5 ± 3.2 9.2 ± 1.0 2.00 ± 0.08 2.00 ± 0.08
Note: statistically significant differences with control group are marked 
by corresponding p value.
Both total FA and potential activity of plasminogen 
are exclusively important indicators of the state of fibri-
nolytic system. The process of plasminogen activation 
into plasmin plays a key role in fibrin clot lysis, but could 
be involved in tumor development by non-functional 
activation of matrix proteinases with following direct 
or mediated destruction of extracellular matrix [29, 
30]. As one may see (Table 3), there is a significant 
slowdown of FA in patients with URT cancer of III stage. 
In both groups of patients a statistically significant 
increase in the potential activity of plasminogen was 
noted.
Таble 3. Indices of fibrinolytic system of blood plasma of patients with 
URT cancer
Groups of patients Clot lysis time, min
Potential plasmin-like 
amidolytic activity, 
nmol p-NA/(min∙ml)
Patients with URT cancer of ІІІ stage 
(n = 25)
263.0 ± 12.0
p < 0.02
0.76 ± 0.06
p < 0.001
Patients with URT cancer of ІІ stage 
(n = 10) 238.0 ± 6.0
0.74 ± 0.10
p < 0.05
Healthy persons (control group)  
(n = 24) 237 ± 5 0.57 ± 0.02
Note: statistically significant differences with control group are marked 
by corresponding p value.
According to the data of postoperative clinical 
observation of the patients with UTR of III stage, 
in 3–12 months after surgical removal of primary 
tumor, 10 patients developed relapse or lymph node 
metastases, and 15 patients were in remission. Pre-
treatment indices of haemostasis system of these 
patients are represented in Table 4. We can see that 
pre-treatment levels of PRA, thrombin-like amidolytic 
and elastase-like amidolytic activities, the contents 
of fibrinogen and α1IP were significantly higher in both 
groups of patients compared to the group of healthy 
persons. Contrary, the level α2M as well as FA were 
considerably lower.
Could all these data be considered useful for the 
evaluation of UTR cancer progression? Combined 
use of the studied indices allowed create an effec-
tive approach based on evaluation of pre-treatment 
level of amidolytic thrombin-like activity, the content 
of fibrinogen and α2M. At the same time, the levels 
of amidolytic elastase-like and PRA remain valuable 
indicators of the general condition of the patients, 
but they were less informative in regard of prognosis 
of disease course in post-treatment period. That’s why 
it seems reasonable to use an additional index ac-
counting the differences between the thrombin-like 
activity and contents of fibrinogen and α2M of each 
patient from their normal levels ([Fg], [Thr] and [α2M]). 
The formula for calculation of such index (let’s name 
it “index H”) is as follows:
H = [Fg][Thr] / [α2M].
By calculation of individual parameters of the 
patients with URT cancer using this formula with follo-
wing use of the methods of variation statistics for both 
groups of patients, the average value of H index for 
the group of patients with complications was 6.35 ± 
1.67 vs 2.65 ± 0.53 for group patients in remission 
(p < 0.05).
In conclusion, the results of combined use of pre-
treatment indices of HS and functionally related pro-
teins of blood plasma in patients with II and III stages 
of URT cancer evidence on association of these indices 
with the disease progression. The level of thrombin-
like amidolytic activity, α2M and fibrinogen contents 
in blood plasma of the patients with URT cancer 
of III stage could be used as valuable index for cancer 
recurrence and metastasis at post-treatment period.
REFERENCES
1. Lukach EV. Larynx cancer. In: Handbook on Oncol-
ogy. Shalimov SA, Grinevich YuA, Vosianov AF, et al., eds. 
Kiev: Zdorovia, 2008: 319–28 (in Russian).
2. Indices of malignancy. In: Clinical biochemistry. 
Tkachuk VA, ed. Tomsk: GEOTAR-MED, 2004: 377–
423 (in Russian).
3. Deskur A, Salata D, Budkowska M, et al. Selected 
hemostatic parameters in patients with pancreatic tumors. 
Am J Transl Res 2014; 6: 768–76.
4. Veremeenko KN, Goloborodko OP, Kizim AI. Prote-
olysis at normal state and pathology. Кyiv: Zdorovia, 1988. 
198 p. (in Russian).
5. Ehrmann M, Clausen T. Proteolysis as a regulatory 
mechanism. Ann Rev Genet 2004; 38: 709–24.
Таble 4. Pre-treatment indices of the groups of patients with URT cancer of III stage with post-operative complications and patients in remission
Groups of patients PRA, nmol Arg/(min∙ml)
Amidolytic 
elastase-like 
activity, nmol 
p-NA/(h∙ml)
Content 
of α1IP, g/l
Content 
of α2М, g/l
Amidolytic 
thrombine-like 
activity, nmol 
p-NA/(min∙ml)
Content of fi-
brinogen, g/l
Clot lysis time, 
min
Patients with relapses of disease or me-
tastasis (n = 10)
81.0 ± 7.2
p < 0,01
14.8 ± 2.3
p < 0.05
2.5 ± 0.2
p < 0.05
1.40 ± 0.10
p < 0.001
20.0 ± 3.9
p < 0.02
4.6 ± 0.4
p < 0.001 278 ± 20
Patients in remission (n = 15) 75.7 ± 3.5
p < 0.001 11.5 ± 1.5 2.10 ± 0.15
1.70 ± 0.10
p < 0.05 12.1 ± 2.7
3.5 ± 0.2
p < 0.001
p1 < 0.05
249 ± 9
Healthy persons (control group) (n = 24) 55.5 ± 3.2 9.2 ± 1.0 2.00 ± 0.08 2.00 ± 0.09 9.6 ± 1.0 2.2 ± 0.1 237 ± 5
Note: p — the difference is significant compared to control group; p1 — the difference between the indices of patients with post-operative complications and 
patients in remission is significant.
Experimental Oncology 38, 36–39, 2016 (March) 39
6. Ogloblina OG, Arefieva TI. Role of proteolytic enzymes 
and their inhibitors in the invasion of malignant tumors. Bio-
chemistry 1994; 59: 340–52 (in Russian).
7. Amour A, Bird M, Chaudry L, et al. General considerations 
for proteolytic cascades. Biochem Soc Trans 2004; 32: 15–6.
8. Zelvyte I, Wallmark A, Piitulainen E, et al. Increased 
plasma levels of serine proteinase inhibitors in lung cancer 
patients. Anticancer Res 2004; 24: 241–7.
9. Benitez-Bribiesca L, de la Huerta-Sanchez R, Villa-
nueva C, et al. Protease-antiprotease balance in patients with 
invasive carcinoma of the cervix and uterus before and after 
radiotherapy. Arch Invest Med 1989; 20: 9–21.
10. Skrzydewska E, Stankiewicz A, Michalak K, et al. 
Antioxidant status and proteolytic-antiproteolytic balance 
in colorectal cancer. Folia Histochem Cytobiol 2001; 
39: 98–9.
11. Buamah PK, Skillen AW. Concentrations of protease 
and anti-protease in serum of patients with pancreatic cancer. 
Clin Chem 1985; 31: 876–7.
12. Sun Z, Yang P. Role of imbalance between neutrophil 
elastase and alpha 1-antitrypsin in cancer development and 
progression. Lancet Oncol 2004; 5: 182–90.
13. Mignatti P, Rifkin DB. Biology and biochemis-
try of proteinases in tumor invasion. Physiol Rev 1993; 
73: 161–95.
14. Mc Intyre J, Matrisian L. Molecular imaging of pro-
teolytic activity in cancer. J Cell Biochem 2003; 90: 1087–97.
15. Borenstain K, Aberson H, Groot AP, et al. A mecha-
nism for thrombin-dependent lung metastasis in patients with 
osteosarcoma. Brit J Heamatol 2009; 145: 533–50.
16. Turpin B, Miller W, Rosenfeldt L, et al. Thrombin 
drives tumorigenesis in colitis-associated colon cancer. Cancer 
Res 2014; 74: 3020–30.
17. Franchini M, Bofanti C, Lippi G. Cancer-associated 
thrombosis investigating the role of new oral anticoagulanrts. 
Thromb Res 2015; 135: 777–81.
18. Liotta L, Ferrari M, Petricoin E. Written in blood. 
Nature 2003; 425: 905.
19. Liotta L, Petricoin E. Serum peptidome for cancer 
detection: spinning biologic trash into diagnostic gold. J Clin 
Invest 2006; 116: 26–30.
20. Kumar S, Rao N, Venudopal LS, Ge R. Endogenous 
angiogenesis inhibitors: is the list ever ending. In: Advances 
in medicine and biology. Berhradt LV, ed. NY: Nova Sci Publs, 
2012; 38: 1–48.
21. Abilgaard U, Lie M, Odegard OR. Antitrombin assay 
with new chromogenic substrates (S-2238 and chromozym 
TH). Tromb Res 1977; 11: 549–53.
22. Veremeenko KN, Kizim AI, Terent’ev AG. Eval-
uatuion of elastase activity and its inhibitors content in blood 
plasma by chromogenic substrates. Clin Lab Diagnost 1992; 
5–6: 58–61 (in Russian).
23. Baluda VP, Barkagan ZS, Goldberg ED, et al. 
In: Laboratory methods for haemostatic study. Tomsk, 1980. 
313 p. (in Russian).
24. Frieberger P, Knos M, Gustavsson S, et al. Methods 
for determination of plasmin, antiplasmin and plasminogen 
by means of substrate S-2251. Haemostasis 1978; 7: 138–45.
25. Belitser VO, Varetska TV, Veremeenko KM, et al. 
Quantitative determination of fibrinogen in human blood 
plasma. Lab Diagnost (Ukr.) 1997; 2: 53–55 (in Ukrainian).
26. Laboratory methods for clinical tests. Menshikova VV, 
ed. Мoscow: Меdicina, 1987: 157–9 (in Russian).
27. Kassenbrock K, Plaks V, Werb Z. Matrix metallo-
proteinases: regulators of the tumor microenvirorment. Cell 
2010; 141: 53–67.
28. Petrosyan AM, Kharchenko VZ. Changed proteinase 
inhibitor system in stomach cancer patients. Oncologia 2007; 
9: 303–6 (in Russian).
29. Van Roozendaal CEP, Klijn JGM, Sieuwerts AM, 
et al. Role of urokinase plasminogen activator in human breast 
cancer: active involvement of stromal fibroblasts. Fibrinolysis 
1996; 2: 79–83.
30. Bergers G, Brekken R, Mc Mahon G, et al. Matrix 
metalloproteinase-9 triggers the angiogenic switch during 
carcinogenesis. Nat Cell Biol 2000; 2: 737–44.
Copyright © Experimental Oncology, 2016
